|Bid||1,684.50 x 175400|
|Ask||1,720.00 x 417900|
|Day's range||1,708.50 - 1,721.50|
|52-week range||1,446.50 - 1,745.56|
|PE ratio (TTM)||50.10|
|Earnings date||26 Jul 2017|
|Dividend & yield||1.00 (4.65%)|
|1y target est||1,789.77|
This one tip could trick you into saving more.
The new chief executive of GlaxoSmithKline (Amsterdam: GO8.AS - news) (GSK) is kicking off her tenure with a move to offload the division which owns Maximuscle, a nutritional products brand favoured by elite athletes. Sky News has learnt that Emma Walmsley, who replaced Sir Andrew Witty at the helm of Britain's biggest drugs manufacturer earlier this year, is pursuing a sale of MaxiNutrition, which was bought in 2010 for £162m. MaxiNutrition, which makes a range of sports nutrition supplements, has partnership deals with England Rugby and teams including London Wasps.
GlaxoSmithKline Plc's new Chief Executive Officer Emma Walmsley is shaking up the British drugmaker's portfolio of smaller products with plans to divest its MaxiNutrition sports nutrition brand, two people familiar with the matter said on Thursday. GSK bought the business, which makes protein bars, drinks and powders, for 162 million pounds ($205 million) in 2010 under previous CEO Andrew Witty. The original acquisition was seen as complementing GSK's Lucozade sports drinks.